Antitumor effect of EBV-CTL adoptive transfer
| Mice . | EBV-CTLs . | EBV-CTLs . | EBV-CTLs . | EBV-CTLs . |
|---|---|---|---|---|
| ΔCD34v . | + rhIL-2 . | iC.ΔCD34/IL-2v . | iC.ΔCD34/IL-15v . | |
| Inoculated with EBV-LCLs | 17 | 24 | 19 | 17 |
| Tumor free 4 to 6 weeks after CTL transfer | 0 | 4 (17%) | 9 (47%)* | 9 (53%)† |
| Mice . | EBV-CTLs . | EBV-CTLs . | EBV-CTLs . | EBV-CTLs . |
|---|---|---|---|---|
| ΔCD34v . | + rhIL-2 . | iC.ΔCD34/IL-2v . | iC.ΔCD34/IL-15v . | |
| Inoculated with EBV-LCLs | 17 | 24 | 19 | 17 |
| Tumor free 4 to 6 weeks after CTL transfer | 0 | 4 (17%) | 9 (47%)* | 9 (53%)† |
ΔCD34v indicates CTLs transduced with the ΔCD34 control vector; iC.ΔCD34/IL-2v, CTLs transduced with the vector encoding for IL-2; iC.ΔCD34/IL-15v, CTLs transduced with the vector encoding for IL-15v. Mice injected with these CTLs did not receive exogenous cytokines. EBV-CTLs indicates CTLs non transduced. Mice infused with control EBV-CTLs received exogenous rhIL-2 (1000 U/mL) intraperitoneally every 2 days.
P = .001.
P < .001 when compared to control EBV-CTLs ΔCD34v by Fisher exact test.